VIVALDIS Animal Health
petsmile
The world of happiness www.vivaldis.co.in
WEEKLY-66

GLOBAL NEWS

FDA Approves First Generic Amoxicillin & Clavulanate Potassium for Oral Suspension for Use in Cats & Dogs[1]

USFDA, August 2021

The U.S. Food and Drug Administration has approved the first generic form of amoxicillin and clavulanate potassium for oral suspension for use in cats and dogs. Amoxicillin and Clavulanate Potassium for Oral Suspension is approved to treat susceptible skin and soft tissue bacterial infections (e.g., wounds, abscesses, cellulitis, etc.) in both dogs and cats. It is also approved to treat periodontal (gum) bacterial infections in dogs and urinary tract infections (cystitis) due to susceptible strains of E. coli in cats. The drug is a generic version of Clavamox Drops.FDA determined that Amoxicillin and Clavulanate Potassium for Oral Suspension contains no inactive ingredients that may significantly affect the bioavailability of the active ingredient.

Feline infectious peritonitis: hope on the horizon for cats[2]

Vet Times, August 31st 2021



A Bengal kitten with ocular and CNS FIP before (left) and after (right) treatment with remdesivir.

FIP is caused by virulent mutations of feline coronavirus (FCoV) that transform it from a mild & enteric infection into a serious systemic disease. Over recent years, publications have focused on antiviral drugs with the potential to cure cats with experimentally induced & naturally acquired FIP. Unfortunately, until very recently legal formulations of these medications were not commercially available. Remdesivir, a prodrug of GS-441524, is an antiviral drug with a broad-spectrum of activity against RNA viruses. It was originally developed to treat hepatitis C virus & Ebola virus but was then fast-tracked for the treatment of SARS-CoV-2. In Australia, remdesivir has been legally available to vets for several months as a "special" formulation, allowing clinicians to gain experience with this drug for the treatment of cats & kittens with FIP, where it has shown great promise. In the UK, remdesivir is legally available via Gilead Sciences, which holds the patent & manufactures the product for human use. The currently available formulation is Veklury, a powder for reconstitution with water for injection to a final remdesivir concentration of 5mg/ml. Researchers are investigating any beneficial effects of immunostimulants and/or other antiviral drugs, such as interferons or mefloquine, once the course of remdesivir has been completed or if injections are deemed too painful.

Varying immune cell levels in canine brain tumors could provide therapeutic targets[3]

Sciencedaily, August 2021

A new study reveals that high-grade gliomas, or brain tumors, in dogs contained more immune cells associated with suppressing immune response than low-grade gliomas. The work, which is the most extensive examination of immune cell infiltration in canine glioma to date, adds to the body of evidence that these brain tumors might recruit cells that aid in immunosuppression. The findings could have implications for future immunotherapy-based glioma treatments in both humans and dogs.

STUDY

Ocoxin oral solution demonstrates antiviral properties in cellular models

Experimental & Therapeutic Medicine, September 2021

Ocoxin Oral Solution (OOS) and Viusid (VS) are nutritional supplements that include several natural products which affect different cellular functions, such as proliferation or the redox status. In addition, some of their constituent components have been described to exert an antiviral effect. Considering this, it was hypothesized that treatment with OOS and VS could protect from viral infections. In order to evaluate the impact of OOS and VS on viral infection, lentivirus and retrovirus whose genomes coded for green fluorescent protein were used. In addition, and as a second approach to measure viral infection, a hemagglutinin-tagged form of the mitogen-activated protein kinase ERK5 was also inserted in the retroviral vector. Viral particles produced in 293T cells were used to infect HeLa cells in the presence or absence of OOS or VS. It was observed OOS significantly reduced the infection of HeLa cells with both of these viruses. The effect was dose-dependent, reaching a maximum at a 1:100 dilution of OOS. **These results suggested that, in addition to its well-known antitumoral properties, OOS may also inhibit infection with viruses. This effect is relevant since patients receiving oncological therapies are more susceptible to viral infections, and nutritional supplements such as OOS may help in reducing the severity of these potential pathogenic infections.**

VIVALDIS Animal Health
Vivaldis Health & Foods Pvt. Ltd.
Office No. 803/804, Clover Hills Plaza, NIBM Road, Pune- 411048, Maharashtra, India.
Help-line No.: +91 7767922244 | Email : info@vivaldis.co.in | Website : www.vivaldis.co.in

1. https://rb.gy/qz1t0x | 2. https://rb.gy/o9jnfy | 3. https://rb.gy/hdlmk1